| 46.99 0.01 (0.02%) | 07-01 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
SpringWorks Therapeutics, Inc. is a biopharmaceutical company dedicated to identifying, developing, and commercializing innovative therapies for patient populations grappling with rare diseases and various forms of cancer, often those with significant unmet medical needs. The company's most advanced experimental treatment is nirogacestat, an orally administered small molecule that functions as a gamma secretase inhibitor. This drug is currently progressing through Phase III clinical trials for the management of desmoid tumors. Another key asset in their pipeline is mirdametinib, an oral small molecule designed to inhibit MEK. It is being evaluated in Phase 2b clinical studies for neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), and concurrently in Phase 1/2a trials for the same condition. Furthermore, mirdametinib is part of a combination regimen with lifirafenib, currently in Phase 1b/2 clinical assessment for patients with advanced or treatment-resistant solid tumors. The company is also exploring mirdametinib both as a standalone agent and in various combination strategies for solid tumors. Additionally, SpringWorks is advancing BGB-3245, an oral, selective small molecule inhibitor targeting both monomeric and dimeric forms of activating BRAF mutations, which is in Phase I development. SpringWorks has forged strategic alliances, including collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene, focusing on combination therapeutic approaches involving nirogacestat and mirdametinib. They have also secured license agreements, notably with Pfizer Inc. for nirogacestat and mirdametinib. Additional licensing deals include an arrangement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a collection of novel small molecule inhibitors of the TEA Domain, and a separate agreement with Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. Moreover, the company maintains clinical collaboration agreements with several entities, such as Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. Founded in 2017, SpringWorks Therapeutics, Inc. maintains its corporate headquarters in Stamford, Connecticut.
Thu, 14 May 2026
SpringWorks Therapeutics stock (US86960K1088): Merck acquisition costs impact Q1 results - AD HOC NEWS
Wed, 02 Jul 2025
[Form 4] SpringWorks Therapeutics, Inc. Insider Trading Activity - Stock Titan
Tue, 01 Jul 2025
German company completes acquisition of Stamford-based Springworks Therapeutics - Hartford Business Journal
Tue, 01 Jul 2025
Merck KGaA completes acquisition of SpringWorks Therapeutics for $47 per share - Investing.com
Tue, 27 May 2025
SpringWorks Therapeutics (SWTX) Surged on Acquisition News - Yahoo Finance
Mon, 28 Apr 2025
Merck to acquire rare diseases company SpringWorks - The Pharma Letter
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|